Global Antifungal Drugs Market Forecast (2013-2023)
26.02.2019 • Views
Share Embed Flag

Global Antifungal Drugs Market Forecast (2013-2023)

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Antifungal Drugs Market. The report analyses the Antifungal Drugs Market By Drug Type (Azoles, Echinocandins, Polyenes, Others), By Therapeutic Indications (Candidiasis, Aspergillosis, Dermatophytosis, Others). The report analyses the Antifungal Drugs Market, By Region (North America, Europe, Asia Pacific, Rest of the World) and By Country (U.S., Canada, Germany, U.K, France, China, Japan, India) for the historical period of 2013-2017 and the forecast period of 2018-2023.Visit us: http://azothanalytics.com/report/healthcare-pharma/global-antifungal-drugs-market-analysis-by-drug-class-azoles-echinocandins-polyenes-others-by-therapeutic-indications-candidiasis-aspergillosis-dermatophytosis-others-by-region-by-country-2019-edition-opportunities-and-forecast-2013-2023-r28194

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Antifungal Drugs Market. The report analyses the Antifungal Drugs Market By Drug Type (Azoles, Echinocandins, Polyenes, Others), By Therapeutic Indications (Candidiasis, Aspergillosis, Dermatophytosis, Others). The report analyses the Antifungal Drugs Market, By Region (North America, Europe, Asia Pacific, Rest of the World) and By Country (U.S., Canada, Germany, U.K, France, China, Japan, India) for the historical period of 2013-2017 and the forecast period of 2018-2023.Visit us: http://azothanalytics.com/report/healthcare-pharma/global-antifungal-drugs-market-analysis-by-drug-class-azoles-echinocandins-polyenes-others-by-therapeutic-indications-candidiasis-aspergillosis-dermatophytosis-others-by-region-by-country-2019-edition-opportunities-and-forecast-2013-2023-r28194

SHOW MORE
SHOW LESS
ePAPER READ
DOWNLOAD ePAPER
AzothAnalytics7

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

START NOW

<strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>: Analysis By Drug Class (Azoles,<br />

Echinocandins, Polyenes, Others), By Therapeutic Indications<br />

(Candidiasis, Aspergillosis, Dermatophytosis, Others), By Region, By<br />

Country (2019 Edition): Opportunities and <strong>Forecast</strong> (<strong>2013</strong>-<strong>2023</strong>)<br />

• By Region: North America, Europe,<br />

Asia Pacific, and Rest of the world.<br />

• By Country - US, Canada, UK,<br />

Germany, France, , Italy, China,<br />

Japan, India.<br />

January 2019

<strong>Global</strong><br />

Regional<br />

Scope of the Report – Anti-Fungal <strong>Drugs</strong> <strong>Market</strong><br />

Historical<br />

<strong>Forecast</strong><br />

<strong>Market</strong> (By Value)<br />

By <strong>Drugs</strong> Type,<br />

By Value<br />

<strong>2013</strong> 2014 2015 2016 2017 2018 2019 2020 2021 2022 <strong>2023</strong><br />

Azoles <br />

Polyenes <br />

Echinocandins <br />

By Therapeutic<br />

Indications,<br />

By Value<br />

Other <br />

Aspergillosis <br />

Dermatophyt<br />

osis <br />

Candidiasis <br />

Others <br />

Azoles <br />

By <strong>Drugs</strong> Type,<br />

By Value<br />

Polyenes <br />

Echinocandins <br />

Other <br />

Aspergillosis <br />

By Therapeutic<br />

Indications,<br />

By Value<br />

Dermatophyt<br />

osis <br />

Candidiasis <br />

Others <br />

2

Country<br />

Scope of the Report – Anti-Fungal <strong>Drugs</strong> <strong>Market</strong><br />

Historical<br />

<strong>Forecast</strong><br />

<strong>2013</strong> 2014 2015 2016 2017 2018 2019 2020 2021 2022 <strong>2023</strong><br />

Azoles <br />

By <strong>Drugs</strong> Type,<br />

By Value<br />

Polyenes <br />

Echinocandins <br />

Other <br />

By Therapeutic<br />

Indication ,<br />

By Value<br />

Aspergillosis <br />

Dermatophyt<br />

osis <br />

Candidiasis <br />

By Company<br />

By Region<br />

By Country<br />

Others <br />

Merck & Co., GSK, Astellas Pharma, Sanofi, Abbott Laboratories, Bayer, Kramer Laboratories, Novartis, Pfizer.<br />

North America, Europe, APAC and ROW.<br />

USA, Canada, Germany, France, UK, China, Japan and India.<br />

3

Table of Content<br />

S.No Particulars Page No.<br />

1. Research Methodology 27<br />

2. Executive Summary 28<br />

3. Strategic Recommendation 29<br />

3.1 Improve Existing <strong>Antifungal</strong>s 30<br />

3.2 Asia Pacific Region to witness the fastest growth 31<br />

4. <strong>Antifungal</strong> <strong>Drugs</strong> Products Outlook 32<br />

5. <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>: Growth and <strong>Forecast</strong> 40<br />

5.1 By Value (<strong>2013</strong>-2017) 41<br />

5.2 By Value (2018-<strong>2023</strong>) 53<br />

6. <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>: Segmental Analysis 54<br />

6.1 <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class: Breakdown (%) 55<br />

6.1.1 <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, 2017 (%) 55<br />

6.1.2 <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, <strong>2023</strong> (%) 56<br />

6.2 <strong>Global</strong> Azole Class <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 57<br />

6.3 <strong>Global</strong> Echinocandins Class <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 58<br />

6.4 <strong>Global</strong> Polyenes <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 59<br />

6.5 <strong>Global</strong> Other <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 60<br />

6.6 <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong>: <strong>Market</strong> Attractiveness, By Drug Class 61<br />

6.7 <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications : Breakdown(%) 63<br />

6.7.1 <strong>Global</strong> Aspergillus <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 65<br />

6.7.2 <strong>Global</strong> Dermatophytosis <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 65<br />

4

Table of Content<br />

S.No Particulars Page No.<br />

6.7.3 <strong>Global</strong> Candidiasis <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 65<br />

6.6.2 <strong>Global</strong> Other Therapeutic Indications <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 65<br />

7. <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>: Regional Analysis 66<br />

7.1 <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Region : Breakdown (%) 67<br />

7.1.1 <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Region, 2017 (%) 67<br />

7.1.2 <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Region, <strong>2023</strong> (%) 67<br />

8. North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>: Growth and <strong>Forecast</strong> 68<br />

8.1 North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>: Segmental Analysis 68<br />

8.2 North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class: Breakdown (%) 75<br />

8.2.1 North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, 2017 (%) 75<br />

8.2.2 North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, <strong>2023</strong> (%) 75<br />

8.3 North America Azoles <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 76<br />

8.4 North America Echinocandins <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 76<br />

8.5 North America Polyenes <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 76<br />

8.6 North America Others <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 76<br />

8.7 North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications : Breakdown(%) 77<br />

8.7.1 North America Aspergillus <strong>Antifungal</strong> <strong>Drugs</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 78<br />

8.7.2 North America Dermatophytosis <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 78<br />

5

Table of Content<br />

S.No Particulars Page No.<br />

8.7.3 North America Candidiasis <strong>Antifungal</strong> <strong>Drugs</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 78<br />

8.7.4 North America Other Therapeutic Indications <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 78<br />

8.8 North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>: Country Analysis (U.S and Canada) 80<br />

8.8.1 U.S <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value (<strong>2013</strong>-<strong>2023</strong>) 83<br />

8.8.2 U.S <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Drug Class, By Value (<strong>2013</strong>-<strong>2023</strong>) 89<br />

8.8.3 U.S <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications, By Value (<strong>2013</strong>-<strong>2023</strong>) 91<br />

8.8.4 Canada <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value (<strong>2013</strong>-<strong>2023</strong>) 94<br />

8.8.5 Canada <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Drug Class, By Value (<strong>2013</strong>-<strong>2023</strong>) 100<br />

8.8.6 Canada <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications, By Value (<strong>2013</strong>-<strong>2023</strong>) 102<br />

9. Europe <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>: Growth and <strong>Forecast</strong> 104<br />

9.1 Europe <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>: Segmental Analysis 104<br />

9.2 Europe <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class: Breakdown (%) 110<br />

9.1.2 Europe <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, 2017 (%) 110<br />

9.1.3 Europe <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, <strong>2023</strong> (%) 110<br />

6

Table of Content<br />

S.No Particulars Page No.<br />

9.3 Europe Azoles <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 111<br />

9.4 Europe Echinocandins <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 111<br />

9.5 Europe Polyenes <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 111<br />

9.6 Europe <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications : Breakdown(%) 112<br />

9.6.1 Europe Aspergillosis <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 113<br />

9.6.2 Europe Dermatophytosis <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 113<br />

9.6.3 Europe Candidiasis <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 113<br />

9.6.4 Europe Other Therapeutic Indications <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 113<br />

9.7 Europe <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>: Country Analysis (Germany, France, Italy, U.K) 115<br />

9.7.1 Germany <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value (<strong>2013</strong>-<strong>2023</strong>) 118<br />

9.7.2 Germany <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Drug Class, By Value (<strong>2013</strong>-<strong>2023</strong>) 124<br />

9.7.3 Germany <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications, By Value (<strong>2013</strong>-<strong>2023</strong>) 126<br />

9.7.4 France <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value (<strong>2013</strong>-<strong>2023</strong>) 129<br />

9.7.5 France <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Drug Class, By Value (<strong>2013</strong>-<strong>2023</strong>) 134<br />

9.7.6 France <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications, By Value (<strong>2013</strong>-<strong>2023</strong>) 136<br />

9.7.7 UK <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value (<strong>2013</strong>-<strong>2023</strong>) 139<br />

9.7.6 UK <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Drug Class, By Value (<strong>2013</strong>-<strong>2023</strong>) 144<br />

9.7.7 UK <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications, By Value (<strong>2013</strong>-<strong>2023</strong>) 146<br />

7

Table of Content<br />

S.No<br />

Page No.<br />

10. APAC <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>: Growth and <strong>Forecast</strong> 149<br />

10.1 APAC <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>: Segmental Analysis 149<br />

10.2 APAC <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class: Breakdown (%) 154<br />

10.2.1 APAC <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, 2017 (%) 154<br />

10.2.2 APAC <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, <strong>2023</strong> (%) 154<br />

10.3 APAC Azole <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 155<br />

10.4 APAC Echinocandins <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 155<br />

10.5 APAC Polyenes <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 155<br />

10.6 APAC Other <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 155<br />

10.7 APAC <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications : Breakdown(%) 156<br />

10.7.1 APAC Aspergillosis <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 157<br />

10.7.2 APAC Dermatophytosis <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 157<br />

10.7.3 APAC Candidiasis <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 157<br />

10.7.4 APAC Other Therapeutic Indications <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 157<br />

8

Table of Content<br />

S.No Particulars Page No.<br />

10.8 APAC <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>: Country Analysis (China, Japan, and India) 158<br />

10.8.1 China <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value (<strong>2013</strong>-<strong>2023</strong>) 162<br />

10.8.2 China <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Drug Class, By Value (<strong>2013</strong>-<strong>2023</strong>) 168<br />

10.8.3 China <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications, By Value (<strong>2013</strong>-<strong>2023</strong>) 170<br />

10.8.4 Japan <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value (<strong>2013</strong>-<strong>2023</strong>) 173<br />

10.8.5 Japan <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Drug Class, By Value (<strong>2013</strong>-<strong>2023</strong>) 179<br />

10.8.6 Japan <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications, By Value (<strong>2013</strong>-<strong>2023</strong>) 181<br />

10.8.7 India <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value (<strong>2013</strong>-<strong>2023</strong>) 184<br />

10.8.8 India <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Drug Class, By Value (<strong>2013</strong>-<strong>2023</strong>) 189<br />

10.8.9 India <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications, By Value (<strong>2013</strong>-<strong>2023</strong>) 191<br />

11. ROW <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>: Growth and <strong>Forecast</strong> 193<br />

11.1 ROW <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>: Segmental Analysis 193<br />

11.2 ROW <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class: Breakdown (%) 201<br />

11.1.1 ROW <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, 2017 (%) 201<br />

11.1.2 ROW <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, <strong>2023</strong> (%) 201<br />

9

Table of Content<br />

S.No<br />

Page No.<br />

11.3 ROW Azole <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 202<br />

11.4 ROW Echinocandins <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 202<br />

11.5 ROW Polyenes <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 202<br />

11.6 ROW Other <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 202<br />

11.7 ROW <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications : Breakdown(%) 204<br />

11.7.1 ROW Aspergillosis <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 204<br />

11.7.2 ROW Dermatophytosis <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 204<br />

11.7.3 ROW Candidiasis <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 204<br />

11.7.4 ROW Other Therapeutic Indications <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value (<strong>2013</strong>-<strong>2023</strong>) 204<br />

12. <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>: <strong>Market</strong> Dynamics 205<br />

12.1 <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Drivers 206<br />

12.2 <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Restrains 211<br />

12.3 <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Trends 213<br />

13. Porter Five Force Analysis 217<br />

14. SWOT Analysis 218<br />

15. <strong>Antifungal</strong> <strong>Market</strong> – Competitive Landscape 219<br />

10

Table of Content<br />

S.No Particulars Page No.<br />

16. Company Profiles 222<br />

16.1 Merck & Co. 223<br />

16.2 Pfizer 225<br />

16.3 GSK 227<br />

16.4 Novartis 229<br />

16.5 Abbott Laboratories 231<br />

16.6 Astellas Pharma 233<br />

16.7 Bayer 235<br />

16.8 Sanofi 237<br />

16.9 Kramer Laboratories 239<br />

11

List of Figures<br />

Figure No. Figure Title Page No.<br />

Figure 1: <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value, <strong>2013</strong>-2017 (USD Million) 41<br />

Figure 2: Number of People Living With HIV, <strong>2013</strong>-2017 44<br />

Figure 3: Number of New Cases of Cancer, In 2018, By Type, (% of Total) 44<br />

Figure 4: Estimated TB Incidences, By WHO Regions, 2016 45<br />

Figure 5: Prevalence of Diagnosed Autoimmune Diseases, In 2018, By Selected Countries, (% of Total) 45<br />

Figure 6: Burden of <strong>Antifungal</strong> Infections, By Type 45<br />

Figure 7: Generic <strong>Market</strong> Value Share, In 2006 (Left) &2016 (Right), By Region 48<br />

Figure 8: <strong>Global</strong> Prescription and OTC <strong>Drugs</strong> Sales, <strong>2013</strong>-2017, (USD Billion) 49<br />

Figure 9: Expected <strong>Global</strong> Medical Spending in 2020, By Product Type, (% of Total) 49<br />

Figure 10: Expected <strong>Global</strong> Medical Spending in 2020, By Region, (% of Total) 49<br />

Figure 11: <strong>Global</strong> Aged Population (Above 65), <strong>2013</strong>-2017 (% of total) 50<br />

Figure 12: <strong>Global</strong> Aged Population(Above 65), By Country, 2017 (% of total) 50<br />

Figure 13: Healthcare Expenditure (Share of GDP), By Selected Country, <strong>2013</strong>-2017 (In %) 51<br />

Figure 14: GDP Per Capita PPP, By Region, 2018 (in Thousand USD) 51<br />

Figure 15: <strong>Global</strong> Expected Healthcare Industry Outlook 52<br />

Figure 16: Regional Expected Healthcare Industry Growth Rate By Year 2020 52<br />

Figure 17: <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value, <strong>Forecast</strong>, 2018-<strong>2023</strong> (USD Million) 53<br />

Figure 18: <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, 2017 (%) 55<br />

Figure 19: <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, <strong>2023</strong>F (%) 56<br />

Figure 20: <strong>Global</strong> Azoles <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, <strong>2013</strong>-2017 (USD Million) 57<br />

12

List of Figures<br />

Figure No. Figure Title Page No.<br />

Figure 21: <strong>Global</strong> Azoles <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, 2018-<strong>2023</strong>(USD Million) 57<br />

Figure 22: <strong>Global</strong> Echinocandins <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, <strong>2013</strong>-2017 (USD Million) 58<br />

Figure 23: <strong>Global</strong> Echinocandins <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, 2018-<strong>2023</strong>(USD Million) 58<br />

Figure 24: <strong>Global</strong> Polyenes <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, <strong>2013</strong>-2017 (USD Million) 59<br />

Figure 25: <strong>Global</strong> Polyenes <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, 2018-<strong>2023</strong>(USD Million) 59<br />

Figure 26: <strong>Global</strong> Other <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, <strong>2013</strong>-2017 (USD Million) 60<br />

Figure 27: <strong>Global</strong> Other <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, 2018-<strong>2023</strong>(USD Million) 60<br />

Figure 28: <strong>Market</strong> Comparison Chart, By Product Type, <strong>2013</strong>-<strong>2023</strong> (USD Million) 61<br />

Figure 29: <strong>Global</strong> <strong>Market</strong> Attractiveness, By Product Type, <strong>2023</strong>F 62<br />

Figure 30: <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications , 2017 (%) 64<br />

Figure 31: <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications , <strong>2023</strong>F (%) 64<br />

Figure 32: <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications , By Value, <strong>2013</strong>-2017 (USD Million) 65<br />

Figure 33: <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications , By Value, 2018-<strong>2023</strong>(USD Million) 65<br />

Figure 34: <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Region, 2017 (%) 67<br />

Figure 35: <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Region, <strong>2023</strong>F (%) 67<br />

Figure 36: North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, <strong>2013</strong>-2017 (USD Million) 69<br />

Figure 37: United States Spending on Medicines, <strong>2013</strong>-2017 (In USD Billion) 71<br />

Figure 38: Patented and Non-Patented <strong>Drugs</strong> Sales in Canada, <strong>2013</strong>-2016 (USD Billion) 71<br />

Figure 39: North America Diseases Outlook 72<br />

Figure 40: United States health care expenditure per capita,<strong>2013</strong>-2016(USD) 72<br />

13

List of Figures<br />

Figure No. Figure Title Page No.<br />

Figure 41: Canada health care expenditure per capita,<strong>2013</strong>-2016(USD) 72<br />

Figure 42: North America population aged 65 and above, <strong>2013</strong>-2017 (% of total) 73<br />

Figure 43: North America Healthcare Cost Per Capita, 2017 (USD) 73<br />

Figure 44: North America GDP per Capita, <strong>2013</strong>-2017 (USD) 73<br />

Figure 45: North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, 2018-<strong>2023</strong> (USD Million) 75<br />

Figure 46: North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, 2017 (%) 75<br />

Figure 47: North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, <strong>2023</strong>F (%) 75<br />

Figure 48: North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Drug Class, By Value, <strong>2013</strong>-2017 (USD Million) 76<br />

Figure 49: North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications , 2017 (%) 77<br />

Figure 50: North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications , <strong>2023</strong>F (%) 77<br />

Figure 51: North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications , By Value, <strong>2013</strong>-2017 (USD Million) 78<br />

Figure 52: North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>,By Therapeutic Indications , By Value, <strong>2013</strong>-2017 (USD Million) 78<br />

Figure 53: North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications , By Value, <strong>2013</strong>-2017 (USD Million) 81<br />

Figure 54: North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Countries, <strong>2023</strong>F (%) 81<br />

Figure 55: USA <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, <strong>2013</strong>-2017 (USD Million) 83<br />

Figure 56: USA <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, 2018-<strong>2023</strong>(USD Million) 83<br />

Figure 57: United States Fungal Infection Facts & Figures 85<br />

Figure 58: New Patients Diagnosed with HIV in 2017, By Age Group 85<br />

Figure 59: United States Per Capita Spending on Medicines, <strong>2013</strong>-2017 (In USD) 86<br />

Figure 60: Pharmacy & Drug Store Sales in United States, <strong>2013</strong>-2016 (In USD Billion) 86<br />

14

List of Figures<br />

Figure No. Figure Title Page No.<br />

Figure 61: Medical and Healthcare Research & Development Spending, <strong>2013</strong>-2016 (In USD Million) 86<br />

Figure 62: U.S., Population ages 65 and above, <strong>2013</strong>-2017 (% of total) 87<br />

Figure 63: U.S., Population ages 65 and above, <strong>Forecast</strong> (In Millions) 87<br />

Figure 64: U.S., Per Capita Expenditure on Healthcare, 2012-2018E (In USD) 87<br />

Figure 65: U.S., GDP (Current USD), <strong>2013</strong>-2017 (In USD Trillion) 87<br />

Figure 66: USA <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, 2017 (%) 88<br />

Figure 67: USA <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, <strong>2023</strong>F (%) 88<br />

Figure 68: USA <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Drug Class, By Value, <strong>2013</strong>-2017 (USD Million) 89<br />

Figure 69: USA <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications , 2017 (%) 90<br />

Figure 70: USA <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications , 2017 (%) 90<br />

Figure 71: USA <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications , By Value, <strong>2013</strong>-2017 (USD Million) 91<br />

Figure 72: USA <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications , By Value, 2018-<strong>2023</strong>(USD Million) 91<br />

Figure 73: Leading <strong>Antifungal</strong> <strong>Drugs</strong> Companies In The United States of America 92<br />

Figure 74: Canada <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, <strong>2013</strong>-2017 (USD Million) 94<br />

Figure 75: Canada <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, 2018-<strong>2023</strong>(USD Million) 94<br />

Figure 76: Estimated Number of Serious Fungal Infections Cases in Canada, 2014 95<br />

Figure 77: Estimated Number of Mucosal Candidiasis in Canada, 2014 96<br />

Figure 78: Estimated Number of Opportunistic Invasive Fungal Infections Cases in Canada, 2014 96<br />

Figure 79: Estimated Number of Endemic Mycoses Cases in Canada, 2014 96<br />

Figure 80: Estimated Number of Non-Invasive Pulmonary Aspergillosis Cases in Canada, 2014 96<br />

15

List of Figures<br />

Figure No. Figure Title Page No.<br />

Figure 81: Number of Retail Pharmacies in Canada, <strong>2013</strong>-2017 97<br />

Figure 82: Number of Hospitals Establishments in Canada, By Province, 2015 97<br />

Figure 83: Number HIV Cases in Canada, <strong>2013</strong>-2016 97<br />

Figure 84: Canada, Expenditure on Health as a share of GDP, 2012-2017 (in %) 98<br />

Figure 85: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD) 98<br />

Figure 86: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD) 98<br />

Figure 87: Canada <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, 2017 (%) 99<br />

Figure 88: Canada <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, <strong>2023</strong>F (%) 99<br />

Figure 89: Canada <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Drug Class, By Value, <strong>2013</strong>-2017 (USD Million) 100<br />

Figure 90: Canada <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications , 2017 (%) 101<br />

Figure 91: Canada <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications , <strong>2023</strong>F (%) 101<br />

Figure 92: Canada <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications , By Value, <strong>2013</strong>-2017 (USD Million) 102<br />

Figure 93: Canada <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications , By Value, 2018-<strong>2023</strong>(USD Million) 102<br />

Figure 94: Leading <strong>Antifungal</strong> <strong>Drugs</strong> Companies In Canada 103<br />

Figure 95: Europe <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, <strong>2013</strong>-2017 (USD Million) 105<br />

Figure 96: Europe Health Expenditure, By Select Country, 2016 (% of GDP) 107<br />

Figure 97: Europe Population ages 65 years and above (% of total population), <strong>2013</strong>-17 107<br />

Figure 98: Europe, Fungal Infections Burden, (Per 100000 population), By Selected Countries 108<br />

Figure 99: Europe <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, 2018-<strong>2023</strong> (USD Million) 109<br />

Figure 100: Europe <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, 2017 (%) 110<br />

16

List of Figures<br />

Figure No. Figure Title Page No.<br />

Figure 101: Europe <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, <strong>2023</strong>F (%) 110<br />

Figure 102: Europe <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Drug Class, By Value, <strong>2013</strong>-2017 (USD Million) 111<br />

Figure 103: Europe <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications , 2017 (%) 112<br />

Figure 104: Europe <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications , <strong>2023</strong>F (%) 112<br />

Figure 105: Europe <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications , By Value, <strong>2013</strong>-2017 (USD Million) 113<br />

Figure 106: Europe <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications , By Value, 2018-<strong>2023</strong>(USD Million) 113<br />

Figure 107: Europe <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Countries, 2017 (%) 116<br />

Figure 108: Europe <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Countries, <strong>2023</strong>F (%) 116<br />

Figure 109: Germany <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, <strong>2013</strong>-2017 (USD Million) 118<br />

Figure 110: Germany <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, 2018-<strong>2023</strong>(USD Million) 118<br />

Figure 111: Germany, Healthcare Related Statistics, 2017 119<br />

Figure 112: Germany, Leukemia Incidences, 2014 & 2018E 121<br />

Figure 113: Germany, Population ages 65 and above, 2012-2017 (% total) 121<br />

Figure 114: Germany, Cause of Deaths, Percentage Change ,2007-2017 121<br />

Figure 115: Germany, Cause of Deaths, Percentage Change ,2007-2017 121<br />

Figure 116: Germany, HIV Prevalence, <strong>2013</strong>-2017 122<br />

Figure 117: Germany, Prevalence of Cancer, 2018 (% of total) 122<br />

Figure 118: Germany <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, 2017 (%) 123<br />

Figure 119: Germany <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, <strong>2023</strong>F (%) 123<br />

Figure 120: Germany <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Drug Class, By Value, <strong>2013</strong>-2017 (USD Million) 124<br />

17

List of Figures<br />

Figure No. Figure Title Page No.<br />

Figure 121: Germany <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications , 2017 (%) 125<br />

Figure 122: Germany <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications , <strong>2023</strong>F (%) 125<br />

Figure 123: Germany <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By herapeutic Indications , By Value, <strong>2013</strong>-2017 (USD Million) 126<br />

Figure 124: Germany <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By herapeutic Indications , By Value, <strong>2013</strong>-2017 (USD Million) 126<br />

Figure 125: Leading <strong>Antifungal</strong> <strong>Drugs</strong> Companies In Germany 127<br />

Figure 126: France <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, <strong>2013</strong>-2017 (USD Million) 129<br />

Figure 127: France <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, 2018-<strong>2023</strong>(USD Million) 129<br />

Figure 128: France, Healthcare Infrastructure Related Statistics 130<br />

Figure 129: France, Health Expenditure, (% of GDP), 2012-2015 (USD) 132<br />

Figure 130: France, Population Ages 65 and Above (% of total), 2012-2017 132<br />

Figure 131: France, Prevalence of Cancer, 2018, (% of total) 132<br />

Figure 132: France, Spending on Healthcare, 2015 & 2040$, (USD Per Person) 132<br />

Figure 133: France <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, 2017 (%) 133<br />

Figure 134: France <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, <strong>2023</strong>F (%) 133<br />

Figure 135: France <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Drug Class, By Value, <strong>2013</strong>-2017 (USD Million) 134<br />

Figure 136: France <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications , 2017 (%) 135<br />

Figure 137: France <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications , <strong>2023</strong>F (%) 135<br />

Figure 138: France <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications , By Value, <strong>2013</strong>-2017 (USD Million) 136<br />

Figure 139: France <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications , By Value, 2018-<strong>2023</strong>(USD Million) 136<br />

Figure 140: Leading <strong>Antifungal</strong> <strong>Drugs</strong> Companies In France 137<br />

18

List of Figures<br />

Figure No. Figure Title Page No.<br />

Figure 141: U.K <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, <strong>2013</strong>-2017 (USD Million) 139<br />

Figure 142: U.K <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, 2018-<strong>2023</strong>(USD Million) 139<br />

Figure 143: U.K, Health Expenditure, (% of GDP), <strong>2013</strong>-2017 (USD) 141<br />

Figure 144: U.K, Population Ages 65 and Above (% of total), 2012-2017 141<br />

Figure 145: UK, Prevalence of Cancer, 2018, (% of Total) 141<br />

Figure 146: U.K, Spending on Healthcare, 2015 & 2040, (USD Per Person) 141<br />

Figure 147: UK, Healthcare Infrastructure Related Statistics 142<br />

Figure 148: Candidaemia per 100,000 population by region (England, Wales and Northern Ireland), <strong>2013</strong>-2017 142<br />

Figure 149: U.K <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, 2017 (%) 143<br />

Figure 150: U.K <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, <strong>2023</strong>F (%) 143<br />

Figure 151: U.K <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Drug Class, By Value, <strong>2013</strong>-2017 (USD Million) 144<br />

Figure 152: U.K <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications , 2017 (%) 145<br />

Figure 153: U.K <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications , <strong>2023</strong>F (%) 145<br />

Figure 154: U.K <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications , By Value, <strong>2013</strong>-2017 (USD Million) 146<br />

Figure 155: U.K <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications , By Value, 2018-<strong>2023</strong>(USD Million) 146<br />

Figure 156: Leading <strong>Antifungal</strong> <strong>Drugs</strong> Companies In U.K 147<br />

Figure 157: APAC <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, <strong>2013</strong>-2017 (USD Million) 149<br />

Figure 158: GDP Per Capita in APAC, By Select Country, 2016 (In USD) 151<br />

Figure 159: Population ages 65 and above, By Select Country, 2017 (% of total) 151<br />

Figure 160: Cancer Incidences in Asia, (% of Total), 2018 151<br />

19

List of Figures<br />

Figure No. Figure Title Page No.<br />

Figure 161: China, Pharmaceuticals Industry Revenue (USD Billion) 152<br />

Figure 162: Japan, Total <strong>Drugs</strong> <strong>Market</strong>, <strong>2013</strong>-2017, USD Billion 152<br />

Figure 163: India Pharma <strong>Market</strong>, 2015-2017, (USD Billion) 152<br />

Figure 164: APAC <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, 2018-<strong>2023</strong> (USD Million) 153<br />

Figure 165: APAC <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, 2017 (%) 154<br />

Figure 166: APAC <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, <strong>2023</strong>F (%) 154<br />

Figure 167: APAC <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Drug Class, By Value, <strong>2013</strong>-2017 (USD Million) 155<br />

Figure 168: APAC <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications , 2017 (%) 156<br />

Figure 169: APAC <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications , <strong>2023</strong>F (%) 156<br />

Figure 170: APAC <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications , By Value, <strong>2013</strong>-2017 (USD Million) 157<br />

Figure 171: APAC <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications , By Value, 2018-<strong>2023</strong>(USD Million) 157<br />

Figure 172: APAC <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Countries, 2017 (%) 159<br />

Figure 173: APAC <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Countries, <strong>2023</strong>F (%) 159<br />

Figure 174: China <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, <strong>2013</strong>-2017 (USD Million) 162<br />

Figure 175: China <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, 2018-<strong>2023</strong>(USD Million) 162<br />

Figure 176: China, Fungal Infections Facts & Figures 164<br />

Figure 177: China, Number of HIV Patients 165<br />

Figure 178: China, Cancer Incidences ( in Million) 165<br />

Figure 179: China, GDP Growth Per Year, 2015-2019 (In %) 166<br />

Figure 180: China, Share of Urban Population, 2012-2017 (In %) 166<br />

20

List of Figures<br />

Figure No. Figure Title Page No.<br />

Figure 181: China, Total Population, <strong>2013</strong>-2021F (In Billion) 166<br />

Figure 182: China <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, 2017 (%) 167<br />

Figure 183: China <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, <strong>2023</strong>F (%) 167<br />

Figure 184: China <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Drug Class, By Value, <strong>2013</strong>-2017 (USD Million) 168<br />

Figure 185: China <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications , 2017 (%) 169<br />

Figure 186: China <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications , <strong>2023</strong>F (%) 169<br />

Figure 187: China <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications , By Value, <strong>2013</strong>-2017 (USD Million) 170<br />

Figure 188: China <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications , By Value, 2018-<strong>2023</strong>(USD Million) 170<br />

Figure 189: Leading <strong>Antifungal</strong> <strong>Drugs</strong> Companies In China 171<br />

Figure 190: Japan <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, <strong>2013</strong>-2017 (USD Million) 173<br />

Figure 191: Japan <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, 2018-<strong>2023</strong>(USD Million) 173<br />

Figure 192: Japan, Population ages 65 and above, 2012-2017 (% of total) 174<br />

Figure 193: Japan, HIV Prevalence, 2017 176<br />

Figure 194: Japan, Medical Facilities Outlook 176<br />

Figure 195: Japan Healthcare Expenditure Outlook (%) 176<br />

Figure 196: Japan, GDP Growth Per Year, 2015-2019F (In %) 177<br />

Figure 197: Japan, Population ages 65 and above, 2012-2016 (% of total) 177<br />

Figure 198: Japan <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, 2017 (%) 178<br />

Figure 199: Japan <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, <strong>2023</strong>F (%) 178<br />

Figure 200: Japan <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Drug Class, By Value, <strong>2013</strong>-2017 (USD Million) 179<br />

21

List of Figures<br />

Figure No. Figure Title Page No.<br />

Figure 201: Japan <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications , 2017 (%) 180<br />

Figure 202: Japan <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications , <strong>2023</strong>F (%) 180<br />

Figure 203: Japan <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications , By Value, <strong>2013</strong>-2017 (USD Million) 181<br />

Figure 204: Japan <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications , By Value, 2018-<strong>2023</strong> (USD Million) 181<br />

Figure 205: Leading <strong>Antifungal</strong> <strong>Drugs</strong> Companies In Japan 182<br />

Figure 206: India <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, <strong>2013</strong>-2017 (USD Million) 184<br />

Figure 207: India <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, 2018-<strong>2023</strong>(USD Million) 184<br />

Figure 208: India, Fungal Infection Facts & Figures 186<br />

Figure 209: India, Diseases & Medical Industry Outlook 186<br />

Figure 210: India, Population ages 65 and above, <strong>2013</strong>-2017 187<br />

Figure 211: India, Total Population, <strong>2013</strong>-<strong>2023</strong>F (In Billion) 187<br />

Figure 212: Pharma Export From India <strong>Market</strong>, <strong>2013</strong>-2017, (USD Billion) 187<br />

Figure 213: India <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, 2017 (%) 188<br />

Figure 214: India <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, <strong>2023</strong>F (%) 188<br />

Figure 215: India <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Drug Class, By Value, <strong>2013</strong>-2017 (USD Million) 189<br />

Figure 216: India <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications , 2017 (%) 190<br />

Figure 217: India <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications , <strong>2023</strong>F (%) 190<br />

Figure 218: India <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications , By Value, <strong>2013</strong>-2017 (USD Million) 191<br />

Figure 219: India <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications , By Value, 2018-<strong>2023</strong>(USD Million) 191<br />

Figure 220: Leading <strong>Antifungal</strong> <strong>Drugs</strong> Companies In India 192<br />

22

List of Figures<br />

Figure No. Figure Title Page No.<br />

Figure 221: ROW <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, <strong>2013</strong>-2017 (USD Million) 194<br />

Figure 222: Fungal Infection Burden in Latin America & Egypt, By Selected Countries 196<br />

Figure 223: HIV Prevalence in LA&C and MENA (% of total), 2018 197<br />

Figure 224: Cancer Prevalence in MENA (% of total), 2018 197<br />

Figure 225: Cancer Prevalence in Latin America & Caribbean , (% of total), 2018 197<br />

Figure 226: GDP Per Capita in ROW, By Select Country, <strong>2013</strong> (In USD) 198<br />

Figure 227: GDP Per Capita in ROW, By Select Country, 2017 (In USD) 198<br />

Figure 228: Latin America and Caribbean, Population ages 65 and above 2012-2017(% of total) 199<br />

Figure 229: Middle East and North Africa, Population ages 65 and above (% of total) 199<br />

Figure 230: ROW <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, 2018-<strong>2023</strong> (USD Million) 200<br />

Figure 231: ROW <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, 2017 (%) 201<br />

Figure 232: ROW <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Drug Class, <strong>2023</strong>F (%) 201<br />

Figure 233: ROW <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Drug Class, By Value, <strong>2013</strong>-2017 (USD Million) 202<br />

Figure 234: ROW <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications , 2017 (%) 203<br />

Figure 235: ROW <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Therapeutic Indications , <strong>2023</strong>F (%) 203<br />

Figure 236: ROW <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>,By Therapeutic Indications , By Value, <strong>2013</strong>-2017 (USD Million) 204<br />

Figure 237: ROW <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic Indications , By Value, 2018-<strong>2023</strong>(USD Million) 204<br />

Figure 238: Branded <strong>Antifungal</strong> <strong>Drugs</strong> Sales, 2017, (USD Million) 221<br />

Figure 239: Merck & Co., Revenues <strong>2013</strong>-2017(USD Million) 224<br />

Figure 240: Merck & Co., Revenues, By Region, 2017(% of Total) 224<br />

23

List of Figures<br />

Figure No. Figure Title Page No.<br />

Figure 241: Merck & Co., Revenues, By Region, 2017(% of Total) 224<br />

Figure 242: Pfizer, Net Sales, <strong>2013</strong>-2017 (USD Million) 226<br />

Figure 243: Pfizer, Revenue, By Segments, 2017 (%) 226<br />

Figure 244: Vfend, Net Sales, 2015-2017 (USD Million) 226<br />

Figure 245: GSK, Revenues, <strong>2013</strong>-2017 (USD Million) 228<br />

Figure 246: GSK, Revenue, By Region, 2017 (USD Million) 228<br />

Figure 247: GSK, Revenue, By Segments, 2017(%) 228<br />

Figure 248: GSK, Revenue, By Pharmaceuticals Segment, 2017 (USD Million) 228<br />

Figure 249: Novartis, Net Sales, <strong>2013</strong>-2017 (USD Million) 230<br />

Figure 250: Novartis, Revenue, By Segment, 2017(%) 230<br />

Figure 251: Novartis, Revenue, By Region, 2017(%) 230<br />

Figure 252: Abbott Laboratories, Net Sales, <strong>2013</strong>-2017 (USD Million) 232<br />

Figure 253: Abbott Laboratories, Revenue, By Segments, 2017(%) 232<br />

Figure 254: Abbott Laboratories, Revenue, By Regions, 2017(%) 232<br />

Figure 255: Astellas, Net Sales, <strong>2013</strong>-2017 (USD Million) 234<br />

Figure 256: Astellas, Revenue, By Regions, 2017(%) 234<br />

Figure 257: Astellas, Revenue, By Segments, 2017(%) 234<br />

Figure 258: Bayer, Net Sales, <strong>2013</strong>-2017 (USD Million) 236<br />

Figure 259: Bayer, Net Sales, <strong>2013</strong>-2017 (USD Million) 236<br />

Figure 260: Bayer, Revenue, By Segments, 2017(%) 236<br />

24

List of Figures<br />

Figure No. Figure Title Page No.<br />

Figure 261: Sanofi, Net Sales, <strong>2013</strong>-2017 (USD Million) 238<br />

Figure 262: Bio-Rad Revenue, By Region, 2017(%) 238<br />

25

List of Figures<br />

Figure No. Figure Title Page No.<br />

Table 1: Different Types of Common Fungal Diseases 36<br />

Table 2: Different Class of Anti-Fungal <strong>Drugs</strong> 37<br />

Table 3: Common Invasive Fungal Diseases and Their Treatment Options 38<br />

Table 4: Common Invasive Fungal Diseases and Their Treatment Options 39<br />

Table 5: Burden of Fungal Diseases 43<br />

Table 6: <strong>Antifungal</strong> Compounds in Development Stage – By Phases 47<br />

Table 7: EU-5 Socio-Economical Statistics, 2017 48<br />

Table 8: Germany, Fungal Infection Burden 120<br />

Table 9: France, Fungal Infection Burden 131<br />

Table 10: Invasive Fungal Infection Burden In UK 140<br />

Table 11: Estimated <strong>Antifungal</strong> Prevalence in Japan, 2016 175<br />

Table 12: Percentage aged 60 years and over, (2000, 2015, 2030,2050) 210<br />

Table 13: Competitive Landscape - Leading Companies – Sales by Drug Class 220<br />

26

Research Methodology<br />

For our study on <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> market, we have conducted comprehensive secondary research<br />

followed by an extensive primary research. In the process of secondary research, we have scrutinized<br />

industry documents, accessed from open sources, premium databases (Bloomberg, Thomson Reuters,<br />

Factiva, Evaluate Pharma, NCBI) and our internal knowledge base. In the process of primary research, we<br />

have interviewed various industry experts across the value chain of medical industry.<br />

<strong>Market</strong> size of the actual period (<strong>2013</strong>-2017) has been evaluated on the basis of growth trends of the<br />

industry in the last five years, and confirming the findings through primary research. Annual reports of the<br />

companies were scanned to further validate the market size and to estimate the size of various other enduser<br />

sectors. <strong>Market</strong> sizing and growth in the forecast period (2018-<strong>2023</strong>) is estimated through product<br />

mapping, application in end-user industries, growth of allied sectors and historical growth pattern of the<br />

industry. All the relevant data points/ statistics in the forecast period are validated through relevant and<br />

reliable primary sources.<br />

Report Focus: <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong><br />

By Drug Type: Azoles, Polyenes, Echinocandins, Others<br />

By Therapeutic Indications: Aspergillosis, Candidiasis, Dermatophytosis, Others<br />

By Region: North America, Europe, APAC and ROW.<br />

By Country: USA, Canada, Germany, France, UK, China, Japan and India.<br />

27

<strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong><br />

xx<br />

Figure 1: <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value, <strong>2013</strong>-2017 (USD Million)<br />

CAGR: <strong>2013</strong>-2017<br />

xx%<br />

<strong>2013</strong> 2014 2015 2016 2017<br />

Source: Azoth Analytics Estimates<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

28

<strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong><br />

xx<br />

Figure 17: <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By Value, <strong>Forecast</strong>, 2018-<strong>2023</strong> (USD Million)<br />

CAGR: 2018-<strong>2023</strong><br />

xx%<br />

2018 2019 2020 2021 2022 <strong>2023</strong><br />

Source: Azoth Analytics Estimates<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

xx<br />

29

<strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>- By Drug Class<br />

Xx<br />

Figure 18: <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size,<br />

By Drug Class, 2017 (%)<br />

Key Drivers<br />

xx<br />

xx<br />

Azoles Echinocandins Polyenes Others<br />

Source: Azoth Analytics Estimates<br />

xx<br />

30

<strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>- By Drug Class<br />

xxx<br />

Figure 19: <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size,<br />

By Drug Class, <strong>2023</strong>F (%)<br />

Key Drivers<br />

xx<br />

xx<br />

Azoles Echinocandins Polyenes Others<br />

Source: Azoth Analytics Estimates<br />

xx<br />

31

<strong>Global</strong> Azole <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong><br />

<strong>Global</strong> Insulin Pumps <strong>Market</strong>, By Value<br />

Figure 20: <strong>Global</strong> Azoles <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By<br />

Value, <strong>2013</strong>-2017 (USD Million)<br />

Figure 21: <strong>Global</strong> Azoles <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>,<br />

By Value, 2018-<strong>2023</strong>(USD Million)<br />

CAGR <strong>2013</strong>-2017<br />

xx%<br />

CAGR 2018-<strong>2023</strong><br />

xx%<br />

<strong>2013</strong> 2014 2015 2016 2017 2018 2019 2020 2021 2022 <strong>2023</strong><br />

Source: Azoth Analytics Estimates<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

32

<strong>Global</strong> Echinocandins Insulin Pumps <strong>Antifungal</strong> <strong>Market</strong>, <strong>Drugs</strong> By Value <strong>Market</strong><br />

Figure 22: <strong>Global</strong> Echinocandins <strong>Antifungal</strong> <strong>Drugs</strong><br />

<strong>Market</strong>, By Value, <strong>2013</strong>-2017 (USD Million)<br />

Figure 23: <strong>Global</strong> Echinocandins <strong>Antifungal</strong> <strong>Drugs</strong><br />

<strong>Market</strong>, 2018-<strong>2023</strong>(USD Million)<br />

CAGR <strong>2013</strong>-2017<br />

xx%<br />

CAGR 2018-<strong>2023</strong><br />

xx%<br />

<strong>2013</strong> 2014 2015 2016 2017 2018 2019 2020 2021 2022 <strong>2023</strong><br />

Source: Azoth Analytics Estimates<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

33

<strong>Global</strong> Polyenes <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong><br />

<strong>Global</strong> Insulin Pumps <strong>Market</strong>, By Value<br />

Figure 24: <strong>Global</strong> Polyenes <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>,<br />

By Value, <strong>2013</strong>-2017 (USD Million)<br />

Figure 25: <strong>Global</strong> Polyenes <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>,<br />

By Value, 2018-<strong>2023</strong>(USD Million)<br />

CAGR <strong>2013</strong>-2017<br />

xx%<br />

CAGR 2018-<strong>2023</strong><br />

xx%<br />

<strong>2013</strong> 2014 2015 2016 2017 2018 2019 2020 2021 2022 <strong>2023</strong><br />

Xx<br />

Source: Azoth Analytics Estimates<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

34

<strong>Global</strong> Others <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong><br />

<strong>Global</strong> Insulin Pumps <strong>Market</strong>, By Value<br />

Figure 26: <strong>Global</strong> Other <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By<br />

Value, <strong>2013</strong>-2017 (USD Million)<br />

Figure 27: <strong>Global</strong> Other <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By<br />

Value, 2018-<strong>2023</strong>(USD Million)<br />

CAGR <strong>2013</strong>-2017<br />

xx%<br />

CAGR 2018-<strong>2023</strong><br />

xx%<br />

<strong>2013</strong> 2014 2015 2016 2017 2018 2019 2020 2021 2022 <strong>2023</strong><br />

Xx<br />

Source: Azoth Analytics Estimates<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

35

Compound Annual Growth Rate<br />

<strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>- <strong>Market</strong> Attractiveness<br />

Figure 29: <strong>Global</strong> <strong>Market</strong> Attractiveness, By Product Type, <strong>2023</strong>F<br />

Azoles<br />

Echinocandins<br />

Polyenes<br />

<strong>Market</strong> Size (USD Million)<br />

Others<br />

Source: Azoth Analytics Estimates<br />

Azoles demand is expected to remain …<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

36

<strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>- By Application<br />

Candidiasis fungal infections has been providing largest share to the antifungal manufacturers.<br />

Figure 30: <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size,<br />

By Therapeutic Indications , 2017 (%)<br />

Figure 31: <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size, By<br />

Therapeutic Indications , <strong>2023</strong>F (%)<br />

Aspergillosis Dermatophytosis Candidiasis Others<br />

Source: Azoth Analytics Estimates<br />

Aspergillosis Dermatophytosis Candidiasis Others<br />

Source: Azoth Analytics Estimates<br />

37

<strong>Global</strong> North <strong>Antifungal</strong> America <strong>Drugs</strong> Insulin <strong>Market</strong>, Pumps By Therapeutic <strong>Market</strong>, By Indications Value<br />

Figure 32: <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic<br />

Indications , By Value, <strong>2013</strong>-2017 (USD Million)<br />

CAGR <strong>2013</strong>-2017<br />

Aspergillosis: xx%<br />

Dermatophytosis: xx%<br />

Candidiasis: xx%<br />

Other:x xx%<br />

Figure 33: <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic<br />

Indications , By Value, 2018-<strong>2023</strong>(USD Million)<br />

CAGR 2018-<strong>2023</strong><br />

Aspergillosis: xx%<br />

Dermatophytosis: xx%<br />

Candidiasis: xx%<br />

Other: xx%<br />

<strong>2013</strong> 2014 2015 2016 2017 2018 2019 2020 2021 2022 <strong>2023</strong><br />

Aspergillosis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00<br />

Dermatophytosis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00<br />

Candidiasis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00<br />

Others 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00<br />

Xx<br />

Source: Azoth Analytics Estimates<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

38

<strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> - Regional Analysis<br />

North America dominates the global market and expected to create its dominance till <strong>2023</strong>, while APAC<br />

is expected to increase in forecast period.<br />

Figure 34: <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size,<br />

By Region, 2017 (%)<br />

Figure 35: <strong>Global</strong> <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size,<br />

By Region, <strong>2023</strong>F (%)<br />

North America Europe APAC ROW<br />

North America Europe APAC ROW<br />

Source: Azoth Analytics Estimates<br />

Source: Azoth Analytics Estimates<br />

39

North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong><br />

xx<br />

Figure 36: North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, <strong>2013</strong>-2017 (USD Million)<br />

CAGR: <strong>2013</strong>-2017<br />

xx%<br />

<strong>2013</strong> 2014 2015 2016 2017<br />

Source: Azoth Analytics Estimates<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

40

North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong><br />

xx<br />

Figure 45: North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value, 2018-<strong>2023</strong> (USD Million)<br />

CAGR: 2018-<strong>2023</strong><br />

xx%<br />

2018 2019 2020 2021 2022 <strong>2023</strong><br />

Xx<br />

Source: Azoth Analytics Estimates<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

xx<br />

41

North <strong>Global</strong> America Insulin <strong>Antifungal</strong> Pumps <strong>Drugs</strong> <strong>Market</strong>, <strong>Market</strong>- By By Value Drug Class<br />

Figure 48: North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Drug Class, By Value, <strong>2013</strong>-2017 (USD Million)<br />

CAGR <strong>2013</strong>-2017<br />

Azoles: xx%<br />

Echinocandins: xx%<br />

Polyenes: xx%<br />

Others: xx%<br />

CAGR 2018-<strong>2023</strong><br />

Azoles: xx%<br />

Echinocandins: xx%<br />

Polyenes: xx%<br />

Others: xx%<br />

<strong>2013</strong> 2014 2015 2016 2017 2018 2019 2020 2021 2022 <strong>2023</strong><br />

Azoles 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00<br />

Echinocandins 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00<br />

Polyenes 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00<br />

Others 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00<br />

Source: Azoth Analytics Estimates<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

42

North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>- By Therapeutic Indications<br />

xx<br />

Figure 49: North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong><br />

Size, By Therapeutic Indications , 2017 (%)<br />

Figure 50: North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong><br />

Size, By Therapeutic Indications , <strong>2023</strong>F (%)<br />

Aspergillosis Dermatophytosis Candidiasis Others<br />

Source: Azoth Analytics Estimates<br />

Aspergillosis Dermatophytosis Candidiasis Others<br />

Source: Azoth Analytics Estimates<br />

43

North America North America <strong>Antifungal</strong> Insulin <strong>Drugs</strong> Pumps <strong>Market</strong>, <strong>Market</strong>, By Therapeutic By Value Indications<br />

Figure 51: North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>,<br />

By Therapeutic Indications , By Value, <strong>2013</strong>-2017 (USD Million)<br />

Figure 52: North America <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>,<br />

By Therapeutic Indications , By Value, 2018-<strong>2023</strong>(USD Million)<br />

CAGR <strong>2013</strong>-2017<br />

Aspergillosis: xx%<br />

Dermatophytosis: xx%<br />

Candidiasis: xx%<br />

Other:x xx%<br />

CAGR 2018-<strong>2023</strong><br />

Aspergillosis: xx%<br />

Dermatophytosis: xx%<br />

Candidiasis: xx%<br />

Other: xx%<br />

<strong>2013</strong> 2014 2015 2016 2017 2018 2019 2020 2021 2022 <strong>2023</strong><br />

Aspergillosis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00<br />

Dermatophytosis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00<br />

Candidiasis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00<br />

Others 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00<br />

Source: Azoth Analytics Estimates<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

44

USA <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong><br />

<strong>Global</strong> Insulin Pumps <strong>Market</strong>, By Value<br />

Figure 55: USA <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value,<br />

<strong>2013</strong>-2017 (USD Million)<br />

Figure 56: USA <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Value,<br />

2018-<strong>2023</strong>(USD Million)<br />

CAGR <strong>2013</strong>-2017<br />

xx%<br />

CAGR 2018-<strong>2023</strong><br />

xx%<br />

<strong>2013</strong> 2014 2015 2016 2017 2018 2019 2020 2021 2022 <strong>2023</strong><br />

Source: Azoth Analytics Estimates<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

45

USA <strong>Global</strong> <strong>Antifungal</strong> Insulin <strong>Drugs</strong> Pumps <strong>Market</strong>- <strong>Market</strong>, By Drug By Value Class<br />

Figure 68: USA <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Drug Class, By Value, <strong>2013</strong>-2017 (USD Million)<br />

CAGR <strong>2013</strong>-2017<br />

Azoles: xx%<br />

Echinocandins: xx%<br />

Polyenes: xx%<br />

Others: xx%<br />

CAGR 2018-<strong>2023</strong><br />

Azoles: xx%<br />

Echinocandins: xx%<br />

Polyenes: xx%<br />

Others: xx%<br />

<strong>2013</strong> 2014 2015 2016 2017 2018 2019 2020 2021 2022 <strong>2023</strong><br />

Azoles 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00<br />

Echinocandins 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00<br />

Polyenes 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00<br />

Others 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00<br />

Source: Azoth Analytics Estimates<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

46

USA <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>- By Therapeutic Indications<br />

Figure 69: USA <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size,<br />

By Therapeutic Indications , 2017 (%)<br />

Figure 70: USA <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong> Size,<br />

By Therapeutic Indications , <strong>2023</strong>F (%)<br />

Aspergillosis Dermatophytosis Candidiasis Others<br />

Source: Azoth Analytics Estimates<br />

Aspergillosis Dermatophytosis Candidiasis Others<br />

Source: Azoth Analytics Estimates<br />

47

USA <strong>Antifungal</strong> USA Insulin <strong>Drugs</strong> Pumps <strong>Market</strong>, <strong>Market</strong>, By Therapeutic By Value Indications<br />

Figure 71: USA <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic<br />

Indications , By Value, <strong>2013</strong>-2017 (USD Million)<br />

Figure 72: USA <strong>Antifungal</strong> <strong>Drugs</strong> <strong>Market</strong>, By Therapeutic<br />

Indications , By Value, 2018-<strong>2023</strong>(USD Million)<br />

CAGR <strong>2013</strong>-2017<br />

Aspergillosis: xx%<br />

Dermatophytosis: xx%<br />

Candidiasis: xx%<br />

Other:x xx%<br />

CAGR 2018-<strong>2023</strong><br />

Aspergillosis: xx%<br />

Dermatophytosis: xx%<br />

Candidiasis: xx%<br />

Other: xx%<br />

<strong>2013</strong> 2014 2015 2016 2017 2018 2019 2020 2021 2022 <strong>2023</strong><br />

Aspergillosis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00<br />

Dermatophytosis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00<br />

Candidiasis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00<br />

Others 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00<br />

Xx<br />

Source: Azoth Analytics Estimates<br />

Xx<br />

Xx<br />

Xx<br />

Xx<br />

48

About Azoth Analytics Pvt Ltd.<br />

Azoth Analytics (ISO 9001:2015) is a business research and analytics company that creates in-depth research reports and provides customized research<br />

solutions and consulting services. An ISO 9001:2015 certified company, Azoth Analytics adheres to international quality management standard and has strong<br />

commitment to a culture of continuous improvement. The business research and market analysis of Azoth Analytics helps organizations across different<br />

industry verticals solve their business problems. Strategic market sizing and data dredging techniques include secondary research, and primary research<br />

(interviews with management personnel and industry experts). Azoth Analytics provide syndicated and customized market research reports on different<br />

verticals including pharmaceutical and healthcare, oil and gas and power, chemicals, automotive, technology, FMCG, food & beverages and media sectors.<br />

Recent Azoth Analytics Reports<br />

• <strong>Global</strong> Advanced Wound Care <strong>Market</strong>: Analysis By Type (Advanced Wound Dressings, Wound Therapy Devices, Wound Biologics), By<br />

Application (Chronic Wounds, Acute Wounds), By End-User, By Region, By Country (2018 Edition): Opportunities and <strong>Forecast</strong>s (2018-<br />

<strong>2023</strong>)<br />

• <strong>Global</strong> Glaucoma Treatment <strong>Market</strong>: Analysis By Indication, By Drug Class, By Sales Channel, By Region, By Country (2018 Edition):<br />

<strong>Forecast</strong> to <strong>2023</strong> - By Indication (Open Angle, Closed Angle, Secondary, Congenital, Others), By Drug Class (Prostaglandin Analogs,<br />

Beta Blockers, Alpha Agonist, Carbonic Anhydrase Inhibitors)<br />

• <strong>Global</strong> Transdermal Drug Delivery System <strong>Market</strong>: Analysis By Type (Patches, Gels), By Technique (Ionophoresis, Electroporation,<br />

Sonophoresis, Others), By End-User, By Region, By Country (2018 Edition): Trends, Opportunities and <strong>Forecast</strong> (<strong>2013</strong>-<strong>2023</strong>)<br />

49

logo

products

Resources

Company

Terms of service
Privacy policy
Cookie policy
Cookie settings
Imprint
Change language
Made with love in Switzerland
© 2024 Yumpu.com all rights reserved

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!